220 related articles for article (PubMed ID: 29923323)
1. Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
Alfredsson J; Green JB; Stevens SR; Reed SD; Armstrong PW; Angelyn Bethel M; Engel SS; McGuire DK; Van de Werf F; Hramiak I; White HD; Peterson ED; Holman RR;
Diabetes Obes Metab; 2018 Oct; 20(10):2379-2388. PubMed ID: 29923323
[TBL] [Abstract][Full Text] [Related]
2. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
[TBL] [Abstract][Full Text] [Related]
3. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
[TBL] [Abstract][Full Text] [Related]
4. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
Shavadia JS; Zheng Y; Green JB; Armstrong PW; Westerhout CM; McGuire DK; Cornel JH; Holman RR; Peterson ED
Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
[TBL] [Abstract][Full Text] [Related]
5. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
Standl E; Stevens SR; Armstrong PW; Buse JB; Chan JCN; Green JB; Lachin JM; Scheen A; Travert F; Van de Werf F; Peterson ED; Holman RR;
Diabetes Care; 2018 Mar; 41(3):596-603. PubMed ID: 29311155
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
Nauck MA; McGuire DK; Pieper KS; Lokhnygina Y; Strandberg TE; Riefflin A; Delibasi T; Peterson ED; White HD; Scott R; Holman RR
Cardiovasc Diabetol; 2019 Sep; 18(1):116. PubMed ID: 31481069
[TBL] [Abstract][Full Text] [Related]
7. Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.
Sharma A; Green JB; Dunning A; Lokhnygina Y; Al-Khatib SM; Lopes RD; Buse JB; Lachin JM; Van de Werf F; Armstrong PW; Kaufman KD; Standl E; Chan JCN; Distiller LA; Scott R; Peterson ED; Holman RR;
Diabetes Care; 2017 Dec; 40(12):1763-1770. PubMed ID: 28986504
[TBL] [Abstract][Full Text] [Related]
8. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
Pagidipati NJ; Zheng Y; Green JB; McGuire DK; Mentz RJ; Shah S; Aschner P; Delibasi T; Rodbard HW; Westerhout CM; Holman RR; Peterson ED;
Am Heart J; 2020 Jan; 219():47-57. PubMed ID: 31707324
[TBL] [Abstract][Full Text] [Related]
9. [TECOS: confirmation of the cardiovascular safety of sitaliptin].
Scheen AJ; Paquot N
Rev Med Liege; 2015 Oct; 70(10):511-6. PubMed ID: 26727841
[TBL] [Abstract][Full Text] [Related]
10. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
Cornel JH; Bakris GL; Stevens SR; Alvarsson M; Bax WA; Chuang LM; Engel SS; Lopes RD; McGuire DK; Riefflin A; Rodbard HW; Sinay I; Tankova T; Wainstein J; Peterson ED; Holman RR;
Diabetes Care; 2016 Dec; 39(12):2304-2310. PubMed ID: 27742728
[TBL] [Abstract][Full Text] [Related]
11. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Engel SS; Green JB; Huang Z; Josse RG; Kaufman KD; Standl E; Suryawanshi S; Van de Werf F; McGuire DK; Peterson ED; Holman RR;
Diabetes Care; 2017 Apr; 40(4):494-501. PubMed ID: 28057693
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Reed SD; Li Y; Leal J; Radican L; Adler AI; Alfredsson J; Buse JB; Green JB; Kaufman KD; Riefflin A; Van de Werf F; Peterson ED; Gray AM; Holman RR;
Diabetes Obes Metab; 2018 Jul; 20(7):1732-1739. PubMed ID: 29573215
[TBL] [Abstract][Full Text] [Related]
13. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
Pagidipati NJ; Navar AM; Pieper KS; Green JB; Bethel MA; Armstrong PW; Josse RG; McGuire DK; Lokhnygina Y; Cornel JH; Halvorsen S; Strandberg TE; Delibasi T; Holman RR; Peterson ED;
Circulation; 2017 Sep; 136(13):1193-1203. PubMed ID: 28626088
[TBL] [Abstract][Full Text] [Related]
14. Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.
Zinman B; Marso SP; Christiansen E; Calanna S; Rasmussen S; Buse JB;
Diabetes Care; 2018 Aug; 41(8):1783-1791. PubMed ID: 29903847
[TBL] [Abstract][Full Text] [Related]
15. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.
McAlister FA; Zheng Y; Westerhout CM; Buse JB; Standl E; McGuire DK; Van de Werf F; Green JB; Armstrong PW; Holman RR;
Eur J Heart Fail; 2020 Nov; 22(11):2026-2034. PubMed ID: 32621557
[TBL] [Abstract][Full Text] [Related]
16. Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial.
Menon V; Lincoff AM; Nicholls SJ; Jasper S; Wolski K; McGuire DK; Mehta CR; Rosenstock J; Lopez C; Marcinak J; Cao C; Nissen SE;
Diabetes Care; 2018 Dec; 41(12):2603-2609. PubMed ID: 30459247
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
De Ferrari GM; Stevens SR; Ambrosio G; Leonardi S; Armstrong PW; Green JB; Wamil M; Holman RR; Peterson ED;
Am Heart J; 2020 Feb; 220():82-88. PubMed ID: 31790905
[TBL] [Abstract][Full Text] [Related]
18. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
Josse RG; Majumdar SR; Zheng Y; Adler A; Bethel MA; Buse JB; Green JB; Kaufman KD; Rodbard HW; Tankova T; Westerhout CM; Peterson ED; Holman RR; Armstrong PW;
Diabetes Obes Metab; 2017 Jan; 19(1):78-86. PubMed ID: 27607571
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan.
Wang SH; Chen DY; Lin YS; Mao CT; Tsai ML; Hsieh MJ; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
PLoS One; 2015; 10(6):e0131122. PubMed ID: 26115092
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
